CD22
B-cell receptor CD22
As of the edition of 20 October 2026, CD22 (B-cell receptor CD22, UniProt P20273) has 14 drugs tested at it and 9 companies on the list, 5 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P20273
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Immune system; Blood and lymph; Cancer; Infections; Skin and connective tissue; Bones, joints and muscles; Heart and blood vessels; Nervous system
- Registered trials of its drugs
- 115
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 3 |
| Went quiet | 5 |
| Stopped | 3 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Inotuzumab ozogamicin | Marketed | Phase 4 | Ends 2031 |
| Epratuzumab | Went quiet | Phase 3 | none listed |
| Moxetumomab pasudotox | Marketed | Phase 3 | Ends 2030 |
| SM03 | Active | Phase 3 | none listed |
| AZD4512 | Active | Phase 2 | none listed |
| BL22 | Stopped | Phase 2 | none listed |
| Pinatuzumab vedotin | Went quiet | Phase 2 | none listed |
| Yttrium y 90 epratuzumab tetraxetan | Stopped | Phase 2 | none listed |
| BAY1862864 | Went quiet | Phase 1 | none listed |
| Epratuzumab-cys-tesirine | Stopped | Phase 2 | none listed |
| Inotuzumab | Marketed | Phase 2 | none listed |
| Mono-dga-rfb4 | Went quiet | Phase 1 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Amgen | Route A |
| Gilead Sciences | Route A |
The other 6 companies at CD22
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at CD22, ranked, with the facts behind eachRequest access. Nothing is shown until you do.